The aim of this study was to assess erythrocyte and plasma copper concentrations and correlate them with the lipid profile of overweight and obese children and adolescents. The study was performed with 15 overweight and 30 obese children and adolescents, and the results were compared to the control group (21), aged 6-16 yr. Anthropometric assessment was carried out using body mass index (BMI). Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride serum levels were investigated. Erythrocyte and plasma copper levels were determined by atomic absorption spectrophotometry. Greater alterations in the lipid profile were observed in HDL-cholesterol, LDL-cholesterol, and triglyceride levels, with distinctions according to gender. The plasma copper concentrations in the overweight and obese male groups were significantly higher than those in the control group (p = 0.0006). Negative correlations between plasma copper and total cholesterol (r = -0.54) and LDL cholesterol (r = -0.59) were observed in the obese male group. There was no statistical difference in copper erythrocyte concentrations. The obesity associated to disorders in lipid metabolism predisposes to changes in copper plasma concentrations, but there was no alteration in intracellular reserves, which suggests an important homeostatic control to compensate for plasma oscillations and metabolic alterations of the disease.
The purpose of this study was to identify the effect of oral zinc supplementation in patients with type 1 diabetes (T1DM) on metabolic control and zinc blood concentrations. The sample consisted of 20 patients with T1DM and a control group (n=17). Metabolic control was evaluated by glycemia at fast, 24 h glycosuria, and HbA1c. Zinc concentrations were measured in plasma and erythrocytes. After the first collection of biological material, oral zinc supplementation was initiated and continued for 4 mo in T1MD patients (T1). Daily dosages were established based on Dietary Recommended Intakes (DRIs), considering zinc intake based on data from other studies previously performed with this population. All analyses were repeated after supplementation (T2). Metabolic control was unsatisfactory, with an HbA1c increase at T2. There was no difference in zinc concentrations in plasma and erythrocytes between patients with T1DM and control. Zinc concentrations in plasma were within the normal range in T1MD before and after supplementation and the control. Zinc concentrations in erythrocyte presented lower than normal values for all groups. A zinc increase in erythrocyte after supplementation was observed in T1DM patients, although without statistical significance. More studies are needed to confirm oral zinc supplementation as nutritional management in diabetes.
This ELISA represents a very practical tool for measuring LDL(-) in human blood for widespread research and clinical sample use.
O zinco apresenta funções catalíticas, estruturais e reguladoras, sendo componente de várias enzimas. Os sintomas observados na deficiência deste elemento incluem lesões de pele, anorexia, retardo do crescimento, hipogonadismo e alteração na função imune. O objetivo desta revisão foi apresentar as funções metabólicas e funcionais do zinco, enfatizando as conseqüências da deficiência e os aspectos que justificam os estudos envolvendo a suplementação com zinco e seus efeitos sobre o crescimento, sistema imunológico e diabetes. Considerando que algumas doenças predispõem o organismo à deficiência de zinco, a suplementação, isoladamente ou associada a outros elementos, demonstra benefícios, especialmente no aumento da velocidade de crescimento, funcionamento do sistema imunológico, diminuição das afecções respiratórias e controle das diarréias. A suplementação em pacientes com diabetes está relacionada com as variáveis do controle metabólico e as concentrações plasmáticas e eritrocitárias de zinco. As estratégias de suplementação com zinco, em populações de risco, devem ser implementadas, considerando-se as doses adequadas de ingestão. Termos de indexação: crescimento, diabetes, sistema imunológico, suplementação, zinco. A B S T R A C T Zinc has catalytic, structural and regulatory functions and is a component of many enzymes. Skin lesions
572Arq ABSTRACT Effect of Zinc Supplementation on Urinary Zinc Excretion of Patients With Type 1 Diabetes.The effect of oral zinc (Zn) supplementation was investigated in children and adolescents with type 1 diabetes (DM1), evaluating their metabolic control and urinary Zn concentrations. Twenty DM1 patients were compared with a control group (n=17); the metabolic control included fasting glucose levels, 24h urinary glucose levels and HbA1c. Zn concentrations were measured in 24h urine before (T1) and after (T2) supplementation. DM1 patients were given oral supplements of tasteless bis-glycine chelated Zn during a 4 month period after the initial collection of baseline data. Doses were established based on the Dietary Reference Intakes. The results demonstrated unsatisfactory metabolic control due to higher HbA1c levels in some patients, after Zn supplementation. Urinary Zn excretion was higher in DM1 patients and disclosed a positive correlation with disease duration and HbA1c levels. Zn supplementation did not correct the heterogeneity of circadian variation in the studied patients, suggesting that inadequate metabolic control in DM may cause disturbances in Zn metabolism, regardless of the dietary or supplemental source.
A aterosclerose é caracterizada por uma resposta inflamatória crônica da parede arterial, iniciada por uma lesão do endotélio, cuja etiologia está relacionada à modificação oxidativa da lipoproteína de baixa densidade. O objetivo deste trabalho é apresentar os principais metabólitos envolvidos nos processos bioquímicos de peroxidação lipídica, discutindo as vantagens e desvantagens dos métodos empregados para a mensuração dos biomarcadores de peroxidação lipídica relacionados com a aterosclerose. A avaliação da oxidação das lipoproteínas pode ser realizada pela determinação dos produtos gerados durante a peroxidação lipídica, como os isoprostanos, hidroperóxidos lipídicos, aldeídos, fosfolípides oxidados e os produtos da oxidação do colesterol. A suscetibilidade das partículas de lipoproteína de baixa densidade à oxidação pode ser avaliada in vitro, após a indução da peroxidação lipídica por azoiniciadores radicalares lipossolúveis, hidrossolúveis, ou mais comumente, pelos íons cobre. Por outro lado, as modificações da lipoproteína de baixa densidade, pela ação das lipoxigenases e peroxidases, ou oxidação não-enzimática, resultam no aumento da carga negativa destas partículas e podem contribuir para a geração in vivo de uma subfração de lipoproteína de baixa densidade minimamente oxidada, denominada lipoproteína de baixa densidade eletronegativa (lipoproteína de baixa densidade). A determinação das concentrações desta partícula pode ser realizada em plasma por cromatografia líquida ou por imunoensaios..Diversos métodos podem ser utilizados para a avaliação dos biomarcadores de peroxidação lipídica in vivo e in vitro, porém, a definição do marcador mais adequado, depende de uma avaliação criteriosa das vantagens, desvantagens e particularidades de cada análise, levando-se em consideração os objetivos do estudo que será conduzido.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.